JP2019524748A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524748A5
JP2019524748A5 JP2019502829A JP2019502829A JP2019524748A5 JP 2019524748 A5 JP2019524748 A5 JP 2019524748A5 JP 2019502829 A JP2019502829 A JP 2019502829A JP 2019502829 A JP2019502829 A JP 2019502829A JP 2019524748 A5 JP2019524748 A5 JP 2019524748A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
carcinoma
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019502829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524748A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2017/026212 external-priority patent/WO2018016563A1/en
Publication of JP2019524748A publication Critical patent/JP2019524748A/ja
Publication of JP2019524748A5 publication Critical patent/JP2019524748A5/ja
Withdrawn legal-status Critical Current

Links

JP2019502829A 2016-07-20 2017-07-20 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用 Withdrawn JP2019524748A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364440P 2016-07-20 2016-07-20
US62/364,440 2016-07-20
PCT/JP2017/026212 WO2018016563A1 (en) 2016-07-20 2017-07-20 Use of eribulin and histone deacetylase inhibitors in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2019524748A JP2019524748A (ja) 2019-09-05
JP2019524748A5 true JP2019524748A5 (cg-RX-API-DMAC7.html) 2020-08-27

Family

ID=60993053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019502829A Withdrawn JP2019524748A (ja) 2016-07-20 2017-07-20 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用

Country Status (4)

Country Link
US (1) US20190282541A1 (cg-RX-API-DMAC7.html)
EP (1) EP3487492A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019524748A (cg-RX-API-DMAC7.html)
WO (1) WO2018016563A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US20190046513A1 (en) * 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
JP7169125B2 (ja) * 2018-08-29 2022-11-10 株式会社日立製作所 質問回答システム、質問回答処理方法、及び質問回答統合システム
CN113271977A (zh) * 2018-11-09 2021-08-17 G1治疗公司 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案
WO2022048527A1 (zh) * 2020-09-01 2022-03-10 深圳微芯生物科技股份有限公司 西达本胺联合雌激素受体下调剂治疗乳腺癌的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067543A2 (en) * 2007-11-19 2009-05-28 The Regents Of The University Of Colorado Treatment of histone deacetylase mediated disorders
GEP201706612B (en) * 2011-09-02 2017-02-10 Novamedica Llc Methods for the treatment of breast cancer
CN105492007A (zh) * 2013-05-03 2016-04-13 欣达克斯制药公司 癌症治疗方法

Similar Documents

Publication Publication Date Title
Gao et al. Ketamine use in current clinical practice
EP3487492A1 (en) Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
JP6539345B2 (ja) がん治療のための医薬組成物の調製におけるデュロキセチン塩酸塩薬物の使用
Sasamura et al. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation
Kast et al. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
Cormio et al. Noninfiltrative anesthesia for transrectal prostate biopsy: a randomized prospective study comparing lidocaine-prilocaine cream and lidocaine-ketorolac gel
JP2020523355A (ja) 肉腫を処置することへの使用のためのチノスタムスチン
JP5123935B2 (ja) 選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法
JP2017507151A5 (cg-RX-API-DMAC7.html)
JP2015508765A5 (cg-RX-API-DMAC7.html)
Meng et al. The combination of paeoniflorin and metformin synergistically inhibits the progression of liver fibrosis in mice
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2022534826A (ja) 炎症性腸疾患及びその腸管外発現の処置のためのアドレナリン作動性β2受容体アゴニストのR-エナンチオマーの新たな使用
Chung et al. Protective effect of 7-hydroxyl-1-methylindole-3-acetonitrile on the intestinal mucosal damage response to inflammation in mice with DSS-induced colitis
Wong et al. Motility of the equine gastrointestinal tract: Physiology and pharmacotherapy
WO2019017497A1 (en) USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER
Chen et al. Neuromuscular blocking agents and cancer: a narrative review
CN104640538B (zh) 包含ndga 衍生物和索拉非尼的组合物以及其在治疗癌症中的用途
EP3117835A1 (en) Il-8 inhibitors for use in the treatment of certain urological disorders
JP2017502989A5 (cg-RX-API-DMAC7.html)
Kiso et al. A novel 5-HT3 receptor agonist, YM-31636, increases gastrointestinal motility without increasing abdominal pain
Guo et al. Drug screening identifies pyrrolidinedithiocarbamate ammonium ameliorating DSS-induced mouse ulcerative colitis via suppressing Th17 differentiation
Hong et al. The effect of intravesical electrical stimulation on bladder function and synaptic neurotransmission in the rat spinal cord after spinal cord injury
Yamamoto et al. THU0398 Efficacy of rituximab and other immunosuppressants for IgG4-related disease